RCKT – rocket pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
10/16
08:44 am
rckt
Medium
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
9/30
12:18 pm
rckt
Low
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $38.00 price target on the stock.
9/30
05:46 am
rckt
Low
Arrhythmogenic Cardiomyopathy (ACM) Market Research Report 2024: US and EU5 Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access [Yahoo! Finance]
9/17
11:11 am
rckt
Low
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $52.00 price target on the stock.
9/17
07:00 am
rckt
Medium
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
8/5/2024
04:01 pm
rckt
0.9%
IN-LINE
5/6/2024
04:01 pm
rckt
0.7%
BEAT
2/26/2024
04:01 pm
rckt
3.2%
BEAT
2/22/2024
04:05 pm
rckt
1.0%
BEAT
10/16
10:14 am
Initiates
Sector Outperform
Scotiabank
Low
2.0%
10/16
10:14 am
Initiates
Sector Outperform
Scotiabank
Low
2.0%
10/16
08:44 am
Initiates
Sector Outperform
Scotiabank
Medium
6.5%
10/16
08:44 am
Initiates
Sector Outperform
Scotiabank
Medium
6.5%
9/30
11:29 am
Maintains
Buy
Buy
Canaccord Genuity
Low
-1.3%
11/4
04:06 pm
rckt
Low
Form 4 ROCKET PHARMACEUTICALS, For: Oct 31 Filed by: Militello John
11/4
04:06 pm
rckt
Low
Form 4 ROCKET PHARMACEUTICALS, For: Oct 31 Filed by: White Mark Andrew
10/31
03:34 pm
rckt
Low
Form 144 ROCKET PHARMACEUTICALS, Filed by: Militello John
10/31
03:25 pm
rckt
Low
Form 144 ROCKET PHARMACEUTICALS, Filed by: White Mark Andrew
10/29
05:06 pm
rckt
Low
Form 4 ROCKET PHARMACEUTICALS, For: Sep 26 Filed by: Bjork Elisabeth
Show more
Top News Gainers
3/19 Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease 32.9%
12/6 Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 “Process B” for Fanconi Anemia 12.8%
9/11 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at William Blair. 12.7%
10/15 Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress 8.2%
12/13 Rocket Pharmaceuticals Announces Closing of Public Offering 7.3%
9/6 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at William Blair. 6.5%
4/2 Rocket Pharmaceuticals Announces Participation at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day 6.5%
9/10 Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine 6.0%
9/4 Form 4 ROCKET PHARMACEUTICALS, For: Sep 02 Filed by: Militello John 5.8%
2/11 Form 8-K ROCKET PHARMACEUTICALS, For: Feb 10 5.2%
Top News Decliners
3/12 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $33.00 price target on the stock. -20.5%
12/10 Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock -14.0%
3/11 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock. -12.4%
3/26 Form 4 ROCKET PHARMACEUTICALS, For: Mar 24 Filed by: Shah Gaurav -9.5%
3/6 Form 10-K ROCKET PHARMACEUTICALS, For: Dec 31 -7.8%
3/17 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.9%
5/22 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.2%
9/26 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) is now covered by analysts at Piper Jaffray Companies. They set an "overweight" rating on the stock. -4.9%
4/1 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.7%
3/5 Rocket Pharmaceuticals Reports Full Year 2019 Financial Results and Operational Highlights -4.6%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3